Company · founded 1998

Trellis Bioscience (United States)

Menlo Park, United States · trellisbio.com

Manage this page

Citations, last 5 years: 93
Works, last 5 years: 10
h-index: 43
Scientists listed: 1
Grants since 2016: 21

Grants received

2024–2025 · cooperative agreement · U44

Bacterial Pneumonia Therapeutic Antibody Safety Trial

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$297.9k

2020–2023 · research · R44

Biofilm disrupting antibody to treat respiratory and musculoskeletal infections

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$999.2kOrthopedic Infections and Treatments

2020–2021 · cooperative agreement · U44

HCMV Therapeutic Antibody Safety Trial

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$299.7kCytomegalovirus and herpesvirus research

2020–2023 · research · R44

Biofilm disrupting antibody to treat respiratory and musculoskeletal infections

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$989.3kOrthopedic Infections and Treatments

2020–2025 · cooperative agreement · U44

HCMV Therapeutic Antibody Safety Trial

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$998.1kCytomegalovirus and herpesvirus research

2020–2023 · research · R44

Biofilm disrupting antibody to treat respiratory and musculoskeletal infections

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$990.9kOrthopedic Infections and Treatments

2020–2025 · cooperative agreement · U44

HCMV Therapeutic Antibody Safety Trial

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$998.1kCytomegalovirus and herpesvirus research

2016–2018 · research · R44

Therapeutic antibody for RSV

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$1.3MRespiratory viral infections research

2016–2017 · research · R44

Therapeutic antibody for RSV

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$1.5MRespiratory viral infections research

2016–2021 · research · R44

Therapeutic Antibody for RSV IIB

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$997.7kRespiratory viral infections research

2016–2021 · research · R44

Therapeutic Antibody for RSV IIB

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$1MRespiratory viral infections research

2016–2021 · research · R44

Therapeutic Antibody for RSV IIB

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$1MRespiratory viral infections research

2015–2020 · grant · SB1

Therapeutic Antibodies for Biofilm Infections

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$1,000k

2015–2021 · grant · SB1

Therapeutic Antibodies for Biofilm Infections

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$1,000k

2015–2020 · grant · SB1

Therapeutic Antibodies for Biofilm Infections

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$1,000k

2014–2023 · research · R44

Strain-Independent Therapeutic Antibodies for Influenza

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$999.8k

2014–2023 · research · R44

Strain-Independent Therapeutic Antibodies for Influenza

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$999.2k

2014–2023 · research · R44

Strain-Independent Therapeutic Antibodies for Influenza

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$999.5k

2012–2020 · grant · SB1

Therapeutic Antibody for CMV

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$999kCytomegalovirus and herpesvirus research

2012–2021 · grant · SB1

Therapeutic Antibody for CMV

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$999.4kCytomegalovirus and herpesvirus research

2012–2020 · grant · SB1

Therapeutic Antibody for CMV

Lawrence Michael Kauvar · Trellis Bioscience (United States) · funded by National Institutes of Health

$997.6kCytomegalovirus and herpesvirus research